Terumo Blood and Cell Technologies and PhotonPharma to Develop Cancer Immunotherapy

Terumo Blood and Cell Technologies and PhotonPharma announced a collaboration to develop a novel tumor-specific immunotherapy for solid tumors.

Terumo Blood and Cell Technologies, a medical device company, and PhotonPharma, a cancer immunotherapy developer, announced in an August 11, 2021 press release a memorandum of understanding (MOU) for collaboration to develop innocell, a novel tumor-specific immunotherapy for solid tumors.

The MOU/initial agreement details the following:

  • PhotonPharma will use Terumo's mirasol pathogen reduction technology in the manufacturing process to develop cancer immunotherapy.
  • PhotonPharma is authorized to reference the device master file on record with FDA for the Mirasol system, which will support PhotonPharma’s regulatory submission for innocell.
  • Terumo Blood and Cell Technologies is to supply mirasol illuminators and single-use sets for the preparation process of the immunotherapy used in the clinical trial.

Since 2007, Terumo's mirasol has been used in select markets outside the United States. It was designed to reduce pathogen load and inactivate residual white blood cells in whole blood and blood components.

Source: Terumo